Thoracal Radiotherapy and Tarceva

Cancer Clinical Trial

— ThoRaT  

Official title:

Concomitant Radiotherapy and Erlotinib in Advanced Lung Cancer

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02714530
• Other study ID #: ThoRaT
• Status: Terminated
• Phase: Phase 2
• Start date: April 1, 2014
• Est. completion date: December 30, 2020

Study information

• Verified date: March 2021
• Source: Oslo University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine if erlotinib given orally along with concurrent palliative irradiation to lung cancer improves local control compared to those treated with radiotherapy alone.

Description:

Endpoints:

Primary:

• To determine if erlotinib given orally along with concurrent external beam radiation therapy, prolongs local tumour control as determined by CT evaluation compared to treatment with external beam radiation therapy alone

Secondary:

• To confirm the safety profile of erlotinib along with concurrent external beam radiation therapy.

• To evaluate if erlotinib along with concurrent external beam radiation therapy, improve quality of life as assessed with the EORTC QLQ-C30 and the EORTC QLQ-LC13.

• To evaluate if PET-CT examination can be used to predict response to treatment.

• To evaluate overall survival in the different groups

Trial Design: Open multicenter two-armed randomized phase II trial.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 118
• Est. completion date: December 30, 2020
• Est. primary completion date: December 30, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age >18 years

• Histological or cytological verified NSCLC

• Palliative radiotherapy to thorax indicated

• ECOG Performance status 0-2

• Fertile patients must use contraception

• Signed informed consent

• Ability to understand and fill in QoL questionnaires

• Capability to take per os medication

• Serum bilirubin < 2 times upper limit of normal (ULN)

• AST and ALT < 2 times ULN (< 5 times ULN if liver metastases are present)

• Creatinine < 5 times ULN

Exclusion Criteria:

• Pregnancy or nursing

• Other prior or concurrent malignant disease likely to interfere with study treatment or comparisons

• No evidence of other significant laboratory finding or concurrent uncontrolled medical illness, that in the opinion of the investigator, would interfere with study treatment or results comparison or render the patient at high risk for treatment complications

• No prior radiotherapy to the same organ / place

• No concurrent treatment with other experimental drugs

• Known brain metastases in need of radiotherapy

• Known hypersensitivity to erlotinib or other substances in the erlotinib tablets.

Related Conditions & MeSH terms

• Cancer

Intervention

Drug:
• Erlotinib
Tarceva daily during radiotherapy course

Radiation:
• Radiation
Radiotherapy

Locations

Country	Name	City	State
Norway	Oslo University Hospital	Oslo	International/Other
Norway	St Olavs Hospital	Trondheim

Sponsors (1)

Lead Sponsor	Collaborator
Oslo University Hospital

Country where clinical trial is conducted

Norway, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of patients with progression in radiation field among patients treated with erlotinib combined with radiotherapy compared to radiotherapy alone	Evaluate local control by radiological evaluation	1 year
Secondary	Number of Participants With Treatment-Related Adverse Events grade >3 as Assessed by CTCAE v4.0	To confirm the safety profile of erlotinib along with concurrent external beam radiation therapy.	1 year
Secondary	Overall survival will be measured	To evaluate overall survival in the different groups	1 year